Enjoy complimentary customisation on priority with our Enterprise License!
The global chronic kidney disease (CKD) drugs market size is estimated to grow by USD 3.81 billion at a CAGR of 4.77% between 2023 and 2028.
Growing awareness about the importance of the early detection and diagnosis of CKD is an important driver propelling the growth of the global CKD drugs market. Public health campaigns, medical education initiatives, and raised access to information related to the importance of treating chronic diseases, such as CKD, have collectively elevated awareness regarding the risk factors and symptoms associated with CKD. Furthermore, early detection is important in controlling CKD effectively, as interventions at the early stages can help slow down disease progression and mitigate difficulties. The focus on routine screenings, mainly for people with risk factors such as diabetes and hypertension, has become a focal point of healthcare strategies on CKD across the globe. Consequently, rising awareness about the significance of the early detection and diagnosis of CKD is anticipated to fuel the growth of the market during the forecast period.
Technavio has segmented the market into Drug Class, Route Of Administration, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the erythropoietin stimulating agents segment will be significant during the forecast period. ESAs play an important role in the management of CKD by managing the issue of anemia, a typical complication associated with impaired kidney function. In CKD patients, the lowered ability of the kidneys to produce erythropoietin leads to anemia, contributing to fatigue and a reduced oxygen-carrying capacity in the blood. ESAs help relieve anemia by stimulating the bone marrow to produce more red blood cells, thereby improving hemoglobin levels and alleviating the symptoms related to anemia.
Get a glance at the market contribution of various segments Download PDF Sample
The erythropoietin stimulating agents segment was valued at USD 4.0 billion in 2018. Several pharmaceutical firms provide the ESA class of drugs as part of their product portfolios. In addition, ESAs include an important role in the therapeutic approach for managing anemia in CKD patients, improving their quality of life, and addressing a significant aspect of the disease. Consequently, the rising use of the ESA class of drugs, owing to their benefits in treating CKD-induced anemia, is expected to drive the growth of the chronic kidney disease drugs market during the forecast period.
The oral route of administration plays an important role in the delivery of medications for the management of CKD. The oral route of administration is a preferred and commonly used approach for CKD drugs, delivering comfort and ease of use for patients undergoing prolonged treatment for CKD. The oral route is particularly suitable for drugs that require systemic distribution and those aimed at addressing conditions or complications associated with CKD, such as hypertension, anemia, and mineral and bone disorders. In addition, the increasing consumption of oral medications for CKD is expected to drive the growth of the oral segment of the chronic kidney disease drugs market during the forecast period.
The subcutaneous route of administration is a vital method for giving medications for the management of CKD. Subcutaneous administration is often used for CKD drugs that require a steady and sustained release, therefore delivering a more prolonged therapeutic effect. Compared with oral medications, this allows the medication to enter the bloodstream more quickly; however, in the case of anemia, it might take a few weeks for the body to start making more red blood cells. Furthermore, Aranesp (darbepoetin alfa) and Procrit (epoetin alfa) are the two main injectable treatment options currently available for anemia in patients with CKD. Thus, such factors will fuel the growth of the subcutaneous segment of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The US and Canada accounted for the largest market shares in the region. The growth of the chronic kidney disease (CKD) drugs market in North America can be attributed to the high prevalence of CKD in the region, the existence of advanced healthcare infrastructure, and the strong presence of the leading chronic kidney disease drugs market players.
Furthermore, the key CKD drugs market players in the region continue to drive innovation in CKD therapeutics by leveraging their extensive R&D capabilities and ensuring a robust market presence and the availability of diverse treatment options for the growing population affected by CKD in North America, which thereby will continue to drive the growth of the regional chronic kidney disease (CKD) drugs market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abbott Laboratories: The company offers chronic kidney disease drugs such as bardoxolone methyl, which is the first medicine to demonstrate improvement in kidney function in patients.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The rising prevalence of CKD is the key factor driving market growth. Chronic kidney disease (CKD) is one of the most typical non-communicable chronic diseases in the world today. The rising number of people diagnosed with diabetes is one of the major contributing causes to the rising prevalence of chronic kidney disease. Diabetes, hypertension, vascular disease, and glomerulonephritis are some of the major causes of CKD. In most underdeveloped and developing countries, glomerulonephritis and interstitial nephritis are the two major causes of CKD, owing to the high prevalence of infections.
In addition, CKD is also associated with an increased risk of cardiovascular disease, infections, diabetes, and cancer. Therefore, the rising prevalence of CKD worldwide is expected to increase the need for CKD drugs, which will subsequently raise the growth of the global CKD drugs market during the forecast period.
Technological innovations in CKD treatment is the primary trend shaping market growth. Technological inventions are improving diagnostics, treatment modalities, and patient care. One significant innovation is the integration of digital health solutions, such as telehealth platforms and mobile applications, which facilitate remote patient monitoring and engagement. Such technologies allow real-time data collection, permitting healthcare providers to track the progression of CKD, dedication to medication among patients, and patient outcomes more effectively.
Furthermore, artificial intelligence (AI) and machine learning are being employed to analyze large datasets and identify patterns that can lead to better treatment decisions. AI applications can assist in predicting disease progression, optimizing the dosages of CKD drugs, and personalizing treatment plans based on individual patient characteristics. Therefore, technological inventions in CKD treatment are anticipated to fuel the growth of the global CKD drugs market during the forecast period.
Growing competition from generic CKD drugs is a challenge that affects market growth. As most of the patents on original branded CKD medications part, generic versions that deliver more cost-effective alternatives to CKD patients enter the market. Significant examples include generic formulations of ACE inhibitors like enalapril and lisinopril, as well as generic versions of angiotensin receptor blockers (ARBs) such as losartan. While they are bioequivalent to their branded counterparts, these generic CKD drugs typically come at a lower cost, leading to increased market adoption.
Moreover, the availability of generic CKD drugs exercises a low pressure on the prices of other branded medications for CKD, thereby negatively affecting the revenue streams of the original manufacturers. The challenge lies in balancing the affordability delivered by generics with the need for constant innovation and the development of more advanced CKD treatments, which provide the sustained growth of market players in an increasingly competitive market landscape. Thus, such factors may impede the growth of the global CKD drugs market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Chronic Kidney Disease (CKD) Drugs Market Customer Landscape
The chronic kidney disease (CKD) drugs market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
Chronic Kidney Disease (CKD) Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
184 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.77% |
Market Growth 2024-2028 |
USD 3.81 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.57 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cara Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd., Novartis AG, OPKO Health Inc., Pfizer Inc., Pharmacosmos AS, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xenetic Biosciences Inc., Zydus Lifesciences Ltd., Ardelyx Inc., and Aurinia Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.